Document Detail


Targeting the vasoprotective axis of the renin-angiotensin system: a novel strategic approach to pulmonary hypertensive therapy.
MedLine Citation:
PMID:  20556668     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A decade has passed since the discovery of angiotensin-converting enzyme 2 (ACE2), a component of the ACE2-angiotensin (Ang)-(1-7)-Mas counterregulatory axis of the renin angiotensin system (RAS). ACE2 is considered an endogenous regulator of the vasoconstrictive, proliferative, fibrotic, and proinflammatory effects of the ACE-Ang II-angiotensin II type 1 receptor (AT(1)R) axis. Both animal and clinical studies have emerged to define a role for ACE2 in pulmonary arterial hypertension (PAH). There is scientific evidence supporting the concept that ACE2 maintains the RAS balance and plays a protective role in PAH. The activation of pulmonary ACE2 could influence the pathogenesis of PAH and serve as a novel therapeutic target in PAH. Current therapeutic strategies and interventions have limited success, and PAH remains a fatal disease. Thus, more research that establishes the novel therapeutic potential and defines the mechanism of the ACE2-Ang-(1-7)-Mas counterregulatory axis in PAH is needed.
Authors:
Chastity N Bradford; Debra R Ely; Mohan K Raizada
Related Documents :
16533328 - Efficacy of oral tadalafil, a new long-acting phosphodiesterase-5 inhibitor, for the sh...
7718958 - Pulmonary hypertension and antiphospholipid antibody in a patient with sjögren's syndr...
23799968 - Effects of genes and environment on the fetoplacental arterial microcirculation in mice...
19466418 - The effects and mechanisms of mycophenolate mofetil on pulmonary arterial hypertension ...
22527178 - Hybrid treatment of a ruptured aneurysm in the distal aortic arch: report of a case.
23908868 - New technologies in coronary artery surgery.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current hypertension reports     Volume:  12     ISSN:  1534-3111     ISO Abbreviation:  Curr. Hypertens. Rep.     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-07-28     Completed Date:  2011-06-02     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  100888982     Medline TA:  Curr Hypertens Rep     Country:  United States    
Other Details:
Languages:  eng     Pagination:  212-9     Citation Subset:  IM    
Affiliation:
Department of Physiology and Functional Genomics, College of Medicine, University of Florida, PO Box 100274, Gainesville, FL 32610, USA. cbradford@ufl.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensin II Type 1 Receptor Blockers / therapeutic use
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Antihypertensive Agents / therapeutic use*
Cardiovascular Diseases / prevention & control
Humans
Hypertension, Pulmonary / drug therapy*,  physiopathology
Lung Diseases / drug therapy
Peptidyl-Dipeptidase A / drug effects*
Renin-Angiotensin System / drug effects*
Signal Transduction / drug effects
Grant Support
ID/Acronym/Agency:
T32 HL083810-04/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; EC 3.4.15.1/Peptidyl-Dipeptidase A; EC 3.4.17.-/angiotensin converting enzyme 2
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Chemoradiotherapy in the treatment of inoperable high-grade osteosarcoma.
Next Document:  Alterations of cortical GABA neurons and network oscillations in schizophrenia.